Non fibrotic hepatocellular carcinoma

Show results for

Unknown (56)
Transcriptomics (45)
Genomics (19)
Proteomics (2)
Metabolomics (1)

Organisms

Mus musculus (23)
Homo sapiens (20)
Rattus norvegicus (5)
Meriones unguiculatus (1)
blank sample (1)
Alphavirus (1)
Anemia (1)
Betaherpesvirinae (1)
Cowpox virus (1)
Coxsackievirus (1)
Cytomegalovirus (1)
Dengue virus (1)
EFO:0001352 (1)
Filoviridae (1)
Hepatitis B virus (1)
Human alphaherpesvirus 1 (1)
Human betaherpesvirus 5 (1)
Human immunodeficiency virus (1)
Human immunodeficiency virus 1 (1)
Human immunodeficiency virus 2 (1)
Influenza A virus (1)
Influenza C virus (1)
Japanese encephalitis virus group (1)
Lyssavirus rabies (1)
Middle East respiratory syndrome-related coronavirus (1)
Mus musculus (1)
Nostoc sp. PCC 7120 = FACHB-418 (1)
Oropouche virus (1)
Orthopoxvirus vaccinia (1)
Rattus (1)

Organisms

Mus musculus (5)
Homo sapiens (4)
Rattus norvegicus (2)
unidentified (1)
Rattus rattus (1)
Meriones unguiculatus (1)

Repository

biostudies-arrayexpress (35)
ENA (16)
geo (13)
iProX (1)
MetaboLights (1)
pride (1)

Tissue

Liver (1)

Disease

Hepatocellular carcinoma (1)

Technology Type

Mass spectrometry (1)
ITRAQ reagent (1)
Mass Spectrometry (1)

Instrument Platform

Illumina HiSeq 1500 (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2015 (8)
2014 (8)
2012 (7)
2016 (6)
2024 (5)
2010 (4)
2011 (3)
2008 (3)
2013 (2)
2019 (1)
2026 (1)
2022 (1)
2020 (1)
2018 (1)

Metabolite Name

Adefovir Dipivoxil (Preveon, Hepsera) (1)
Indomethacin (Indocid, Indocin) (1)
MLS001148580-01!6ALPHA,9ALPHA-DIFLUOROPREDNISOLONE 21-ACETATE 17-BUTYRATE (1)
Toremifene Citrate (Fareston, Acapodene) (1)
[(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate (1)
(+)-Cycloolivil 4'-O-¦Â-D-glucopyranoside (1)
(+)-Lyoniresinol 2¦Á-O-¦Â-D-glucopyranoside (1)
(-)-Hydroxymatairesinol (1)
(-)-Medicocarpin;Medicarpin 3-O-glucoside (1)
(-)-Pyrifolidine (1)
(-)-Syringaresinol-4-O-¦Â-D-glucopyranoside (1)
(-)-threo-Iso(homo)2-citrate;(-)-threo-1-Hydroxy-1,2,5-pentanetricarboxylic acid;1-Hydroxypentane-1,2,5-tricarboxylate;threo-(Homo)2-isocitrate (1)
(1)Benzopyrano(5,4,3-cde)(1,3)dioxolo(4,5-h)(1)benzopyran-5,11-dione, 1,2,3-trimethoxy- (1)
(1,3-Dihydroxy-6,8a-dimethyl-3-propan-2-yl-1,2,3a,4,5,8-hexahydroazulen-4-yl) 3,4-dimethoxybenzoate (1)
(10-Hydroxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl) (Z)-2-methylbut-2-enoate (1)
(11E)-11-Octadecenoic acid (1R,2S)-2-[[(Z)-9-hexadecenoyl]oxy]-1-methylpropyl ester (1)
(11E)-4-((2,6-Dideoxy-4-O-(2-methoxy-6-methylbenzoyl)hexopyranosyl)oxy)-22-hydroxy-15,21a-dimethyl-18,21-dioxo-1,2,3,4,4a,6a,7,8,9,10,12a,15,16,21,21a,21b-hexadecahydro-16a,19-(metheno)benzo[e]naphtho[2,1-m][1,4]dioxacyclopentadecine-14(18H)-carboxylic acid (1)
(12Z)-9,10,11,14,15,16,17,18,19,20,21,22-Dodecahydro-5,8-ethenobenzo[20]annulene-2,4,6,24-tetrol (1)
(13S)-13-Ethoxy-1,2-dimethoxy-12-methyl-13H-[1,3]benzodioxolo[5,6-c]phenanthridine (1)
(14E)-11-hydroxy-14-(1H-imidazol-5-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.01,13.03,8]hexadeca-3,5,7-triene-12,15-dione (1)
(14E)-2,11-dihydroxy-14-(1H-imidazol-5-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.01,13.03,8]hexadeca-3,5,7,10-tetraene-12,15-dione (1)
(14S)-9,20,21,25-Tetramethoxy-15-methyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-1(30),3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,28,31-tetradecaen-2-one (1)
(19E,21E,23E,25E,27E,29E,31E)-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,33,37-pentahydroxy-18,36-dimethyl-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-9,13,15-trione (1)
(19E,21E,23E,25E,27E,29E,31E)-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,33,37-hexahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate (1)
(1E)-4-hydroxy-1-(4-hydroxy-3-methoxyphenyl)dodec-1-en-3-one (1)
(1E,3Z)-buta-1,3-diene-1,2,4-tricarboxylate (1)
(1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-7-ol (1)
(1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-1,2,3,4,5,6,7,11b-octahydrobenzo[a]quinolizin-5-ium-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-6-ol (1)
(1R,10R)-5-amino-14-oxido-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4-diene-7,11-dione (1)
(1R,14R,24S)-24-Methoxy-5,7,19,21,25-pentaoxa-13-azahexacyclo[12.11.0.02,10.04,8.015,23.018,22]pentacosa-2,4(8),9,15(23),16,18(22)-hexaene (1)

First Public Date

2024 (5)
2015 (3)
2026 (2)
2018 (2)
2022 (1)
2020 (1)
2016 (1)
2014 (1)

Study type

Transcription profiling by array (31)
Comparative genomic hybridization by array (1)
ChIP-seq (1)
RNA-seq of coding RNA (1)
RNA-seq of non coding RNA (1)

Release Date

2021 (12)
2015 (9)
2020 (8)
2012 (7)
2016 (6)
2014 (6)
2023 (6)
2019 (5)
2018 (5)
2011 (4)
2010 (4)
2022 (4)
2013 (3)
2008 (3)
2025 (3)
2024 (3)
2026 (2)
2017 (1)

Lab affiliation

Inserm U1053, Université Bordeaux 2, France (1)

Previous page
1 / 13
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 13
Next page

Sort by:

Relevance

Page size

iTRAQ proteomics of non fibrotic carcinoma on Human Liver

We present a study of hepatocellular carcinoma developed on non-fibrotic liver (nfHCC) that combines complementary quantitative iTRAQ-based proteomics and phosphoproteomics approaches. Using both approaches, we analyzed a set of 24 samples (18 nfHCC vs 6 non-tumor liver tissue).

ORGANISM(S): Homo sapiens (Human)

2014-09-18 | PXD001253 | Pride

MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule

Tumor cells were microdissected from FFPE sections of hepatocellular carcinoma (HCC) samples. Samples were compared between different localisations either within or around the tumor. miRNA was labeled with the Affymetrix FlashTag Biotin HSR RNA Labeling Kit 6 microdissected hepatocellular carcinoma ...

ORGANISM(S): Homo sapiens

2015-01-14 | E-GEOD-54537 | biostudies-arrayexpress

Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression

The proteins binding Sema3C and NRP1 in hepatocellular carcinoma cells were analyzed by mass spectrometry

ORGANISM(S): Homo Sapiens

2024-06-03 | PXD052807 |

Induction of hepatocellular carcinoma through activation of stromal cells in Pdgf-c transgenic mice

Liver cirrhosis is a strong risk factor for the development of hepatocellular carcinoma (HCC), yet the mechanisms by which cirrhosis predisposes patients to tumorigenesis are not well understood. Transgenic mice expressing platelet-derived growth factor C (Pdgf-c) under the control of the albumin pr...

ORGANISM(S): Mus musculus

2014-05-12 | E-GEOD-38199 | biostudies-arrayexpress

Hepatic transcriptomic changes during non-alcoholic steatohepatitis (NASH)-associated liver carcinogenesis in mice

Hepatocellular carcinoma (HCC), which accounts for 90% of all primary livers tumors, is the fourth most common cancer in the world. The development of HCC is a long-term and complex process, and uncovering the molecular mechanisms associated with HCC development is critical for the disease diagnosi...

ORGANISM(S): Mus musculus

2016-06-22 | E-GEOD-83596 | biostudies-arrayexpress

Transcriptional analysis of non-fibrotic NAFLD progression

PRJNA634922 | ENA

Molecular crosstalk between hepatocytes and hepatic stellate cells.

Aim of the study was to characterize at a molecular level (changes in transcriptomes) the crosstalk between tumor hepatocytes and activated hepatic stellate cells (HSC) in liver cancer. This was adressed by using a coculture model system of HepaRG cell line (tumor hepatocytes, human), and LX2 cell l...

ORGANISM(S): Homo sapiens

2012-05-31 | E-GEOD-32565 | biostudies-arrayexpress

Transcriptional analysis of non-fibrotic NAFLD progression

Background & Aims: Non-alcoholic steatohepatitis (NASH), a subtype of non-alcoholic fatty liver disease (NAFLD) that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma, is characterized by hepatic inflammation. Despite evolving therapies aimed to ameliorate inflammation in NASH, the trans...

ORGANISM(S): blank sample Homo sapiens

2020-07-08 | GSE151158 | GEO

Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.

Not available

S-EPMC7875922 | biostudies-literature

Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

Not available

S-EPMC7384114 | biostudies-literature

Previous page
1 / 13
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 13
Next page

Sort by:

Relevance

Page size

123 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

Metabolite Name

First Public Date

Study type

Release Date

Lab affiliation

OmicsDI is part of the ELIXIR infrastructure

Tweets